🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesMetabolic syndrome reversal — May 2025

Metabolic syndrome reversal — May 2025

james_edin Mon, Oct 27, 2025 at 11:27 PM 6 replies 1,096 viewsPage 1 of 2
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Oct 27, 2025 at 11:27 PM#1

A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

What I am after is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

Not looking for reassurance. Looking for the part I have got wrong.

49 19mona_PHX, andrew_nyc, Dr.EndoEP and 46 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Oct 27, 2025 at 11:35 PM#2
james_edin said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 12 months: periods became regular for the first time in ever, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my hormonal symptoms have almost completely resolved.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

48 18tommy_boulder, hyun_seoul, jim_asheville and 45 others
Reply Quote Save Share Report
COA_Karl
Senior Member
2,123
8,901
Jan 2024
Pennsylvania
Oct 27, 2025 at 11:43 PM#3
Dr.PeteFamMed said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 36% to 22%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: Oct 28, 2025 at 12:43 AM
47 17hyun_seoul, jim_asheville, matt_MKE and 44 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
SkepticalSean
Member
98
345
Jan 2025
Maine
Oct 27, 2025 at 11:51 PM#4
james_edin said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

This matches mine closely enough to be worth saying so out loud.

46 16tammy_FL, Dr.LipidDallas, alex_tucson and 43 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Oct 28, 2025 at 12:31 AM#5

Adding the clinical framing, because it changes how the question reads.

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 24 → 12 → 5 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

45 15amy_econ_NJ, bbq_ray_KC, oliver_london and 42 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register